A5054060709- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Cell death mechanisms and regulation
- Cancer-related Molecular Pathways
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Galectins and Cancer Biology
- Calcium signaling and nucleotide metabolism
- Multiple Myeloma Research and Treatments
- Synthesis and pharmacology of benzodiazepine derivatives
- Acute Lymphoblastic Leukemia research
- Telomeres, Telomerase, and Senescence
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- NF-κB Signaling Pathways
- Phagocytosis and Immune Regulation
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Synthesis and Biological Evaluation
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- DNA Repair Mechanisms
Brighton and Sussex Medical School
2018-2025
University of Sussex
2018-2024
St. Antonius Ziekenhuis
2024
CorVita Science Foundation
2024
Liverpool Heart and Chest Hospital
2024
Leeds Teaching Hospitals NHS Trust
2022
Cardiff University
2011-2021
Guy's and St Thomas' NHS Foundation Trust
2021
University of Leeds
2006-2018
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2014
The subcutaneous implantable cardioverter-defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the ICD cannot provide bradycardia and antitachycardia pacing. Whether modular pacing-defibrillator system comprising leadless pacemaker in wireless communication to pacing safe remains unknown.
Although CD49d is an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL), definitive validation evidence lacking. A worldwide multicenter analysis was performed using published and unpublished CLL series to evaluate the impact of as overall (OS) treatment-free survival (TFS) predictor.A training/validation strategy chosen find optimal cutoff. The hazard ratio (HR) for death treatment imposed by estimated pooled 2,972 CLLs; Cox stratified center stage used adjust confounding...
Patients with chronic lymphocytic leukemia (CLL) display immune deficiency that is most obvious in advanced stage disease. Here we investigated whether this dysfunction plays a pathologic role the progression of early disease patients.We carried out eight-color immunophenotyping analysis cohort 110 untreated CLL patients and 22 age-matched healthy donors correlated our findings clinical outcome data.We found significant reduction naive CD4(+) CD8(+) T cells patients. Only subset showed...
Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival and reinstates apoptosis cancer cells. We designed series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached the C5-position pyrimidine or C4-thiazol moiety investigated their effects on potency selectivity. One most selective compounds, 12u inhibits IC(50) = 7 nM shows over 80-fold selectivity versus CDK2. X-ray...
Abstract Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however, much of the heritable risk remains unidentified. Here we perform a meta-analysis six genome-wide association studies, imputed using merged reference panel 1,000 Genomes and UK10K data, totalling 6,200 cases 17,598 controls after replication. We identify nine at 1p36.11 (rs34676223, P =5.04 × 10 −13 ), 1q42.13 (rs41271473, =1.06 −10 4q24 (rs71597109, =1.37 4q35.1 (rs57214277, =3.69 −8 6p21.31...
The bcl-2 gene was first shown to be dysregulated in the majority of follicular lymphomas which a t(14;18) chromosomal translocation is present, but also over-expressed absence rearrangements most cases B-cell chronic lymphocytic leukaemia (B-CLL). oncoprotein regulator apoptosis and activity this protein opposed by bax, homologous that accelerates rate cell death. B-lymphocyte bax levels were found significantly altered B-CLL patients when compared those normal control group. Increased...
Chronic lymphocytic leukemia (CLL) cells rapidly undergo apoptosis in vitro, suggesting that the vivo microenvironment provides crucial antiapoptotic signals. Overexpression of proteins Bcl-2 and Mcl-1 is a hallmark CLL, their expression further enhanced lymphoid tissues. However, high levels found peripheral blood samples, coupled with its short half-life, led us to hypothesize it must be actively maintained circulation. Coculture CLL human vascular endothelial significantly tumor cell...
Summary Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. Here we assessed ability high‐resolution single telomere length analysis ( STELA ), combined with an experimentally derived definition dysfunction, to predict outcome patients chronic lymphocytic leukaemia CLL ). We defined upper threshold at which fusions occur and then used mean ‘fusogenic’ range as prognostic tool. Patients telomeres within fusogenic had significantly shorter overall...
// Elisabeth Walsby 1 , Guy Pratt 2 Hao Shao 3 Abdullah Y. Abbas Peter M. Fischer Tracey D. Bradshaw Paul Brennan Chris Fegan Shudong Wang 3,4 and Pepper Cardiff CLL Research Group, Institute of Cancer & Genetics, School Medicine, University, Heath Park, Cardiff, UK. CRUK for Studies, University Birmingham, Pharmacy Centre Biomolecular Sciences, Nottingham, 4 Medical South Australia, Adelaide, Australia. Correspondence: Pepper, email: Keywords : CLL, cdk9, synergy, MCL1 Received November 3,...
Chronic lymphocytic leukemia is an incurable B-cell malignancy that associated with tumor cell-mediated T-cell dysfunction. It therefore represents a challenging disease for immunotherapeutics. The CD19/CD3 bi-specific antibody construct blinatumomab (AMG103 or MT103) has been tested clinically in non-Hodgkin's lymphoma and acute lymphoblastic but not assessed chronic leukemia. We investigated whether could overcome dysfunction vitro. Blinatumomab was on peripheral blood mononuclear cells...
Abstract In this study we conducted the first investigation to assess efficacy of a novel therapeutic antibody developed target annexin-A1 (ANXA1). ANXA1 is an immunomodulatory protein which has been shown be overexpressed in, and promote development progression of, several cancer types. particular, high expression levels correlate with poorer overall survival in pancreatic triple-negative breast cancers, two cancers considerable unmet clinical need. MDX-124 humanised IgG1 monoclonal...